MBL Wealth LLC Buys 53 Shares of Eli Lilly and Company $LLY

MBL Wealth LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 3.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,611 shares of the company’s stock after purchasing an additional 53 shares during the period. MBL Wealth LLC’s holdings in Eli Lilly and Company were worth $1,256,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Wealthcare Capital Partners LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $256,000. Hill Island Financial LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $341,000. Ergawealth Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 4.0% in the second quarter. Ergawealth Advisors Inc. now owns 626 shares of the company’s stock worth $488,000 after buying an additional 24 shares during the period. Berger Financial Group Inc raised its holdings in shares of Eli Lilly and Company by 2.6% in the second quarter. Berger Financial Group Inc now owns 6,712 shares of the company’s stock worth $5,233,000 after buying an additional 169 shares during the period. Finally, Bay Harbor Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 35.9% in the second quarter. Bay Harbor Wealth Management LLC now owns 178 shares of the company’s stock worth $139,000 after buying an additional 47 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $840.46 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The stock has a fifty day moving average price of $734.60 and a 200-day moving average price of $765.98. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $795.47 billion, a PE ratio of 54.93, a P/E/G ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on LLY shares. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Morgan Stanley dropped their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Saturday, September 27th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $938.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.